BioMarin Pharmaceutical stock

BMRN · NASDAQ · USD

Compare BioMarin Pharmaceutical
$57.23Change from previous close: +0.93%Absolute change: +$0.53

Close · November 13, 2026

Price history

+5.55% over the period

1 year: from $54.22 (November 13, 2025) to $57.23 (November 13, 2026), +5.55%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$57.23
October 30, 2026$58.51
September 30, 2026$60.00
August 31, 2026$65.23
July 31, 2026$60.02
June 30, 2026$57.22
May 29, 2026$57.29
April 30, 2026$53.91
March 31, 2026$56.49
February 27, 2026$61.73
January 30, 2026$56.54
December 31, 2025$59.43
November 28, 2025$55.93
November 13, 2025$54.22

At a glance

  • The company

    Biotechnology company developing and commercializing therapies for rare genetic and metabolic disorders globally

  • Latest results

    Quarter to September 30, 2026 · EPS $0.23 (estimate $1.35)

TickerLandia's take on BioMarin Pharmaceutical

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$49.26
52-wk high$70.98

−19.37% from the 52-week high

Analysts · 28 analysts

Average target$90.78+58.62% vs. price

Buy 21 · Hold 7 · Sell 0 · Buy

TickerLandia Fingerprint: BioMarin Pharmaceutical

Compared with similar companies: high earnings stability, low price, and low risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

BioMarin Pharmaceutical is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), BioMarin Pharmaceutical's P/E today is 31.8, in line with the median of its last 5 fiscal years (33.0; between 19.5 and 138.0 from 2020 to 2025). BioMarin Pharmaceutical's P/E (trailing 12 months): 146.8, +168% against the median of a group of 7 similar companies (54.8).

P/E compared with its history

Compared with 7 similar companies

BioMarin Pharmaceutical's metrics compared with similar companies
MetricBioMarin PharmaceuticalPosition in the groupBand
P/E (trailing 12 months)146.8High
Forward P/E9.05Low
Operating margin16.3%Middle
ROE-0.3%Middle
Debt/equity0.67High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: BioMarin Pharmaceutical. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$989.71M

Latest quarter · Q2 2026

Net income

$44.76M

Latest quarter · Q2 2026

Quarterly net margin

4.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$11.09B
P/E
146.8
EPS
-$0.10
Volume
1.47M
Daily trading
€126.22M
Dividend yield
0.00%

How BioMarin Pharmaceutical is changing

All results
  • Revenue grew 11.6% a year on average over the last 5 years

  • Operating margin rose from 7.7% to 12.7%

  • Profits turn into cash: free cash flow equal to 135% of net income

Returns

BioMarin Pharmaceutical returns

$1,000 invested in BioMarin Pharmaceutical 5 years ago, on November 15, 2021, would be worth $697 today: −30.27% in total, −6.96% per year. This is the price return only: dividends are excluded.

PeriodBioMarin PharmaceuticalS&P 500$1,000 becomes
1 month+5.24%−3.12%$1,052
6 months+6.87%+1.58%$1,069
Year to date−3.70%+10.46%$963
1 year+5.55%+12.23%$1,056
3 years−31.37%+71.41%$686
5 years−30.27%+61.48%$697
10 years−38.40%+249.40%$616

Over the last 6 months it has done better than 34% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

BioMarin Pharmaceutical: technical analysis

BioMarin Pharmaceutical shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 61.6% below its all-time closing high ($149.13, July 20, 2015).

Trend
No clear trend
RSI (14 sessions)
50
Between 30 and 70
vs 200-session average
−2.11%

Support and resistance

Price areas where BioMarin Pharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$60.65+5.98%2 touches, last on July 17, 2026
  2. Resistance$59.39+3.77%3 touches, last on November 2, 2026
  3. Resistance$57.95+1.26%9 touches, last on October 15, 2026
  4. Last price$57.23
  5. Support$53.90−5.82%4 touches, last on October 8, 2026
  6. Support$52.15−8.88%3 touches, last on November 3, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.36
Volatility (60 sessions, annualised)
26.9%
Largest fall in the last year
−22.58%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

BioMarin Pharmaceutical: seasonality

Average monthly price change over 28 years

+4.6%Jan+1.6%Feb+0.2%Mar−2.1%Apr+0.8%May+1.6%Jun+4.0%Jul+0.5%Aug−1.5%Sep−2.6%Oct+6.1%Nov+3.5%Dec

Over the last 28 years, the strongest month for BioMarin Pharmaceutical has been November: +6.09% on average, positive in 22 years out of 27. The weakest has been October: −2.64% on average, positive in 11 years out of 28.

Show chart data
MonthAverageMedianPositive years
January+4.60%+3.30%17 of 27
February+1.61%−2.04%13 of 27
March+0.19%−0.66%12 of 27
April−2.05%0.00%13 of 27
May+0.79%+2.71%14 of 27
June+1.65%+3.63%16 of 27
July+3.99%+3.84%18 of 27
August+0.50%+1.00%16 of 28
September−1.49%−2.75%12 of 28
October−2.64%−3.13%11 of 28
November+6.09%+5.74%22 of 27
December+3.51%+2.49%17 of 27

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

BioMarin Pharmaceutical and its competitors

The company's activity centres on rare-disease therapies, with a portfolio built around enzyme replacement treatments and peptide-based medicines. Its marketed products include VIMIZIM for mucopolysaccharidosis type IV A, VOXZOGO for achondroplasia, NAGLAZYME and ALDURAZYME for other MPS disorders, PALYNZIQ for lowering blood phenylalanine, BRINEURA for Batten disease type 2, and KUVAN for phenylketonuria. Two candidates in development, BMN 333, a longer-acting CNP, and BMN 351, an oligonucleotide for Duchenne muscular dystrophy, extend the pipeline.

Headquarters
San Rafael, United States
Employees
3,221
Founded
1996
Chief executive
Alexander Hardy
BioMarin Pharmaceutical and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
BioMarin PharmaceuticalBMRN$11.09B16.3%146.8+6.87%
Summit TherapeuticsSMMT$11.32B0.0%—−24.69%
Halozyme TherapeuticsHALO$11.43B56.7%25.1+43.18%
Bio-TechneTECH$11.44B21.7%66.8+62.17%
Madrigal PharmaceuticalsMDGL$9.93B-10.7%—−17.63%
BridgeBio PharmaBBIO$15.25B-37.3%—+14.12%

Same industry or related industries, similar size. Compare BioMarin Pharmaceutical with its competitors · Full profile